Zintrodiazine demonstrated a favourable juvenile safety profile, with no adverse effects on growth, neurodevelopment or sexual maturation at clinically relevant exposures. These findings provide critical regulatory data supporting progression into paediatric clinical trials and highlight Zintrodiazine's potential as a safe and effective antimalarial for children.
Kadu et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: